Healthy men test drug for muscular dystrophy
NCT ID NCT07317063
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a single dose of the study drug GRT6019 in 18 healthy men to check its safety and how the body processes it. The study also looked at whether food changes drug absorption. Results will guide future research for Duchenne muscular dystrophy, but this trial did not test the drug in patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY (DMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Biotrial, Inc
Newark, New Jersey, 07103, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug help boys with duchenne muscular dystrophy build muscle protein?
- New drugs aim to slow muscle decline in duchenne muscular dystrophy
- AI-Powered heart scans aim to predict deadly complications in muscular dystrophy
- Wearable sensors could bring duchenne monitoring home
- Could a popular Weight-Loss drug help—or Harm—Those with duchenne muscular dystrophy?
- New drug could help boys with duchenne walk and move longer